When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020.
This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA.
This is in no way a thorough analysis of OMER's pipeline or even just the potential of Narsoplimab (as it has huge potential in other indications).
Following are all the known companies currently developing a competing treatment.
Alexion Pharmaceuticals
Alexion (ALXN) is the behemoth with a $25B market cap and billions of cash at hand. They